ProQuad®

BIOLOGICAL4 trials

Sponsors

Merck Sharp & Dohme LLC, GlaxoSmithKline

Conditions

DiphtheriaHaemophilus InfectionsHepatitis BMeaslesMumpsPertussisPoliomyelitisRubella

Phase 2

Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age

CompletedNCT00578175

GlaxoSmithKlineMeasles, Mumps, Rubella +1

Start: 2007-11-20End: 2009-03-17Updated: 2018-10-09

Phase 3

ProQuad® Intramuscular vs Subcutaneous

CompletedNCT00402831

Merck Sharp & Dohme LLCMeasles, Mumps, Rubella +1

Start: 2006-10-06End: 2007-05-11Updated: 2018-08-13

Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)

CompletedNCT00432042

Merck Sharp & Dohme LLCDiphtheria, Haemophilus Infections, Hepatitis B +7

Start: 2007-01-12End: 2008-03-27Updated: 2018-03-19

Safety Study of ProQuad® rHA in Infants (V221-037)

CompletedNCT00560755

Merck Sharp & Dohme LLCMeasles, Mumps, Rubella +1

Start: 2007-10-24End: 2008-11-24Updated: 2017-10-17

Related Papers

Immunogenicity and safety of intramuscular versus subcutaneous administration of a combined measles, mumps, rubella, and varicella vaccine to children 12 to 18 months of age

Human Vaccines & Immunotherapeutics2018-11-2710 citations

Safety of a 2-dose regimen of a combined measles, mumps, rubella and varicella live vaccine manufactured with recombinant human albumin.

2012-11-015 citations